Quick Answer
AXIM BIOTECHNOLOGIES, INC. reported Total Revenue of $39.5 thousand for the year ending 2023.
- AXIM BIOTECHNOLOGIES, INC. showed an increase of +345.3% in Total Revenue from 2022 to 2023.
- This data is from AXIM BIOTECHNOLOGIES, INC.'s annual report (Form 10-K), filed with the SEC on April 16, 2024.
- XBRL data for this metric is available from 2010 to 2023 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2011: $0.00 | Q2 2011: $0.00 | Q3 2011: $0.00 | Q1 2012: $10.8 thousand | Q2 2012: $10.8 thousand | Q3 2012: $10.8 thousand | Q1 2013: $10.8 thousand | Q2 2013: $10.8 thousand | Q3 2013: $10.8 thousand | Q3 2014: $0.00 | Q3 2015: $21.6 thousand | Q1 2016: $14.0 thousand | Q2 2016: $11.2 thousand | Q3 2016: $9.6 thousand | Q1 2017: $18.6 thousand | Q2 2017: $3.7 thousand | Q3 2017: $9.8 thousand | Q1 2018: $14.2 thousand | Q2 2018: $8.2 thousand | Q3 2018: $6.2 thousand | Q1 2019: $17.1 thousand | Q2 2019: $93.1 thousand | Q3 2019: $403.0 thousand | Q3 2020: $0.00 | Q1 2021: $32.6 thousand | Q2 2021: $14.9 thousand | Q3 2021: $8.1 thousand | Q1 2022: $0.00 | Q2 2022: $0.00 | Q3 2022: $1.3 thousand | Q1 2023: $7.4 thousand | Q2 2023: $9.9 thousand | Q3 2023: $9.6 thousand | Q1 2024: $53.0 thousand | Q2 2024: $17.5 thousand.
- Historical annual values: Fiscal year 2023: $39.5 thousand | Fiscal year 2022: $8.9 thousand | Fiscal year 2021: $60.5 thousand | Fiscal year 2018: $195.6 thousand | Fiscal year 2017: $47.6 thousand | Fiscal year 2016: $47.1 thousand | Fiscal year 2013: $21.7 thousand | Fiscal year 2012: $43.3 thousand | Fiscal year 2011: $10.0 thousand | Fiscal year 2010: $0.00.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: